Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study

• Main Authors: André R. Durães (Author), Yasmin de Souza Lima Bitar (Author), José Admirço L. Filho (Author), Igor S. Schonhofen (Author), Edmundo J. N. Camara (Author), Leonardo Roever (Author), Hugo E. D. P. Cardoso (Author), Kevan M. Akrami (Author)
• Formato: Livro
• Publicado em: Adis, Springer Healthcare, 2018-10-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Introduction Mechanical heart valves (MHV) are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. The only approved therapeutic options are vitamin K antagonists (VKAs), such as warfarin. As a drug class, clinical management is difficult,...